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Pseudokinases-remnants of evolution or key allosteric
regulators?
Elton Zeqiraj1,2 and Daan MF van Aalten3Protein kinases provide a platform for the integration of signal
transduction networks. A key feature of transmitting these
cellular signals is the ability of protein kinases to activate one
another by phosphorylation. A number of kinases are
predicted by sequence homology to be incapable of
phosphoryl group transfer due to degradation of their
catalytic motifs. These are termed pseudokinases and
because of the assumed lack of phosphoryltransfer activity
their biological role in cellular transduction has been
mysterious. Recent structure–function studies have
uncovered the molecular determinants for protein kinase
inactivity and have shed light to the biological functions and
evolution of this enigmatic subset of the human kinome.
Pseudokinases act as signal transducers by bringing together
components of signalling networks, as well as allosteric
activators of active protein kinases.
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Introduction
Protein kinases are involved in orchestrating almost all
aspects of cellular life by integrating cell signalling net-
works. A myriad of studies have described the molecular
basis of protein kinase function. The first structure of a
protein kinase, described by Knighton et al., 1991 uncov-
ered the architecture of the eukaryotic protein kinase
domain and key elements of the enzyme Protein Kinase A
(PKA) catalytic site together with the substrate binding
mode [1,2]. Several structural and sequence homology
studies of protein kinase domains have revealed a con-
sensus of what are the common motifs that are required
Open access under CC BY license.Current Opinion in Structural Biology 2010, 20:772–781for catalytic activity [3,4,5,6,7,8,9] (Figure 1a and b).
These comprise residues that are required for nucleotide
(ATP) binding, metal ion (Mg2+) binding and residues
required for phosphoryl group transfer. There are 518
known human protein kinases [10], representing
approximately 2–2.5% of the estimated total number of
genes in the human genome [11] and the third most
common functional domain [12]. Intriguingly, 10% of
the kinome appear to lack at least one of the motifs
required for catalysis and have been termed pseudoki-
nases [10,13].
Inactive pseudokinases or simply unusual
active kinases?
The subject of pseudokinases has generatedmuch atten-
tion recently [14–17] and remains controversial. For
some proteins that were observed to lack catalytic resi-
dues andwere thus originally classified as pseudokinases,
protein kinase activity was subsequently reported. One
of the best examples of this are the WNK (With No (K)
Lys) protein kinases that activate SPAK and OSR1
kinases by phosphorylation, contributing to the regula-
tion of ion transport and blood pressure (reviewed by
Richardson and Alessi [18]). Interestingly, the WNK1
crystal structure revealed that although a keyLys residue
was missing from the VAIKmotif (found in subdomain II
of the kinase domain), this was structurally compensated
for by a Lys residue present in the neighbouring sub-
domain I [19]. Similar examples of apparent pseudoki-
nases displaying the capacity for phosphoryl transfer
have been reported recently (e.g. CASK [20], IRAK2
[21] andHER3 [22]). Because of these recent findings, it
appears that using variations in the primary sequences of
the catalytic motifs to predict whether a kinase domain
has catalytic activity is not always valid. This suggests
that the bioinformatics prediction of10%of the kinome
being pseudokinases may be an overestimate. Predicted
pseudokinases should thus be studied individually, their
activity be probed with more direct methods and their
structures determined.
Five ways of killing a kinase
A number of recent studies have provided structural
information of pseudokinase domains that have extended
our understanding of their biological functions and the
mechanism of their inactivation. We summarise these
examples below, thus explaining the molecular determi-
nants for protein kinase inactivity and suggest a new set of
criteria for cataloguing the currently predicted pseudoki-
nases (Box 1).www.sciencedirect.com
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Figure 1
Degradation of pseudokinase nucleotide binding pockets and ‘active’ sites. (a) Multiple sequence alignment of pseudokinases and the canonical
protein kinase PKA. Highlighted in green are key residues that are deemed to be essential for activity in eukaryotic protein kinases. (b) Kinase domain
secondary structure, subdomains and conservation of key motifs. The secondary structure is labelled and the consensus sequence of common motifs
and key conserved loops are given. These were deduced from multiple sequence alignments of representative protein kinases from each branch of the
human kinome [28] and the study of Kannan et al., 2007 [9]. The subdomains are labelled using the nomenclature described by Hanks et al., 1988 [3]
and Taylor and Radzio-Andzelm, 1994 [4]. (c–h) Nucleotide binding pockets and active sites of PKA (PDBID 1ATP [1], STRADa (PDBID 3GNI [28], ILK
(PDBID 3KMW; [36], HER3 (PDBID 3KEX; [39], VRK3 (PDBID 2JII; [40]) and ROP2 (PDBID 2W1Z; [44]). ATP is shown as sticks with magenta
carbon atoms. For VRK3 and ROP2, ATP (shown as lines) bound to PKA was modelled in the VRK3 and ROP2 structures by superposition of the PKA
structure (PDBID 1ATP). Glycine residues are depicted as green spheres, water molecules are shown as red spheres, Mn2+ atoms as purple spheres
and Mg2+ as blue spheres. Hydrogen bonding interactions are represented by dashed lines, and residues making up the hydrophobic spine of VRK3
are shown as sticks and transparent surface.
www.sciencedirect.com Current Opinion in Structural Biology 2010, 20:772–781
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Box 1 As more studies are reported that describe pseudokinase
structures, their potential activities and functions, it should be
possible in the future to determine if these are ‘true’ pseudokinases.
Currently, we suggest the following nomenclature for referring to the
group of kinases that have been predicted to be catalytically
inactive:
Group 1. Predicted pseudokinases—These are pseudokinases that
have at least one altered residue in the catalytic site and no structural
and/or biochemical evidence to support either their activity or
inactivity. This currently comprises the largest group, and it remains
a challenge for the future to put them either in one of the following
two groups, or declare them actual kinases.
Group 2. Pseudokinases—These are pseudokinases for which
kinase activity has not been detected and inactivity can be
accounted for by structural or biochemical studies (e.g. STRAD and
ILK). Similarly, pseudokinases that cannot bind ATP (e.g. VRK3 and
ROP2/8) should be included in this group.
Group 3. Low activity kinases—These are predicted pseudoki-
nases for which kinase activity has been detected (e.g. CASK, IRAK2
and HER3/ErbB3), but by comparison to other kinases (often the
closest true kinase paralogue), their activity is very low.
Group 4. Active pseudokinases—These are predicted pseudoki-
nases that are highly active despite missing catalytic motifs. These
members have evolved compensatory mechanisms for the missing
functions of canonical motifs (e.g. WNK1, missing the VAIK motif [19]
and Haspin, missing the DFG motif [23]). It is possible that a sizeable
proportion of Group 1 members will be classified as active upon
further structural and enzymological characterisation.STRADa
The Ste20 related adaptor (STRADa and STRADb)
isoforms are part of the LKB1 heterotrimeric tumour
suppressor complex [24,25]. Together with the adaptor
protein MO25 [26], STRAD activates the LKB1 kinase
through an allosteric mechanism that does not require
LKB1 activation loop phosphorylation [27]. STRAD
lacks six of the eleven catalytically important residues
that are generally required for kinase activity (Figure 1b).
Despite the changes in the glycine-rich loop, (the third
consensus glycine being replaced byMet83 (Figure 1a, c,
and d), the crystal structure of STRADa revealed that
STRADa is capable of binding ATP with low nanomolar
affinity, and retains a kinase fold that that is typical of the
canonical ‘active’ kinase conformation [28]. Curiously,
all catalytic motifs usually required for kinase activity
(Figure 1c), adopt conformations compatible with phos-
phoryl transfer, yet the amino acids on these structural
motifs lack the chemical properties required for catalysis
(Figure 1d). For instance, instead of an Asp residue in the
conservedArg-Aspmotif (Asp166 in PKA, Figure 1c) that
acts as a catalytic base [5,29], a Ser residue (Ser195) is
present in STRADa (Figure 1d). Interestingly, the Asp-
Phe-Gly motif, crucial for binding Mg2+ ions, is changed
to Gly-Leu-Arg in STRADa. The Arg215 side chain
coordinates the b-phosphate group of ATP and together
with His200 they partially substitute the role of Mg2+
ions (Figure 1c and d). The active conformation of
STRADa was shown to be modulated by its binding
partner MO25, as well as ATP [28]. The MO25 inter-Current Opinion in Structural Biology 2010, 20:772–781action is centered around the regulatory helix aC, which
is analogous to the activation of CDKs by cyclins [30,6].
Loss of ATP and MO25 binding impinges on the ability
of STRAD to activate theLKB1kinase [28], suggesting
that the ‘active’ conformation of STRADa plays a key
role. When the structure of the full LKB1 heterotrimer
became available, it was apparent that elements of the
STRADa active and substrate binding sites such as the
activation and substrate binding loops [2] and helix aG
[31,32,33] were involved in binding and activating the
LKB1 kinase (Figure 2a) [27]. The activation loop of
STRADa adopts an extended conformation, reminiscent
of active kinases and is involved in LKB1 binding
(Figure 2a). These data suggest that STRADa engages
LKB1 as a ‘pseudosubstrate’ and explain why STRADa
must adopt an active conformation in order to activate
LKB1 [27,28,16]. Therefore, STRADa appears to
have evolved as a pseudokinase allosteric regulator of
LKB1 no longer requiring the ability to catalyse phos-
phoryl transfer.
ILK
Integrin-linked kinase (ILK) is involved in signalling
from the transmembrane integrin receptor to the actin
cytoskeleton, and as such regulates many cell-adhesion-
dependent processes [34]. ILK is part of a heterotrimeric
complex together with PINCH and parvin (the so-called
IPP complex) [34]. Although ILK lacks six of the eleven
key residues required for catalysis (Figure 1a and b), a
large number of studies have claimed that ILK phos-
phorylates several substrates (reviewed by Legate et al.,
2006). However, these data contradict reports from
genetic studies suggesting that kinase catalytic activity
per se may not be required for IPP complex function
(reviewed by Wickstro¨m et al., 2010 [35]. It is possible
that ILK gains activity under very specific conditions
(e.g. upon post-translational modification and/or allo-
steric activators), which may explain these contradictory
reports. A recent crystal structure of ILK bound to a-
Parvin [36] has uncovered the molecular basis of ILK
function and explains why ILK is incapable of phosphor-
ylating any substrates (Figure 1e). Inactivity is accounted
for by substitutions of the catalytic base (PKA residue
Asp166) with Ala319, the crucial lysine residue from the
catalytic loop (PKA residue Lys168) with Asn321 and a
Mg2+ binding Asn residue (PKA residue Asn171) with
Ser324 (Figure 1c and e). A striking feature of the ILK-a-
parvin complex structure is the presence of ATP in the
ILK nucleotide binding pocket, despite several non-
conservative substitutions of crucial glycine residues in
the glycine-rich loop (Figure 1a and e). The ATP g-
phosphate is also coordinated by a positively charged
residue (Lys341), acquired by a substitution of the con-
served glycine from the canonical DFG motif
(Figure 1e), similar to the interaction between Arg215
of STRADa and the ATP g-phosphate (Figure 1d).
While it is unclear what the function of ATP bindingwww.sciencedirect.com
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Figure 2
Pseudokinases in action. (a) STRADa binding to LKB1 within the LKB1-STRAD-MO25 complex (PDBID 2WTK; [27]). A-segment = activation
segment, defined as the region between the DFG and APE motifs and comprises the activation and substrate binding (p + 1) loops [7]. (b) Structure of
ILK-a-parvin complex (PDBID 3KMW; [36]). (c) Structure of the asymmetric EGFR/EGFR dimer (PDBID 2GS2; [37]). (d) Structure of the BRAF side-
to-side dimer [58] (PDBID 1UWH, [73]).in ILK is, one possible function is that ATP is required
for the active-like conformational state of ILK to bind
parvin molecules. Binding of parvins was wrongly
assumed to activate ILK, as the recent structure by
Fukuda et al. revealed that a-parvin makes use of the
active site of ILK for binding [36]. Thus, a-parvin
bound to the ILK pseudoactive site will sterically hinder
any potential substrates of the ILK-a-parvin complex
(Figure 2b). This is similar to the binding mode of
STRAD and LKB1, where the pseudokinase (STRAD)
makes use of its pseudoactive site and binds its partner
(LKB1) as a pseudosubstrate (Figure 2a). Thus, struc-
tures of the ILK-a-parvin complex and the LKB1-
STRAD-MO25 complex show a recognition mode be-
tween pseudokinaseswith theirmacromolecular partnerswww.sciencedirect.comthat is similar to the knownkinase–substrate interactions.
Further examples of this will need to be uncovered to
establish this as a general mechanism of interaction.
HER3
HER3/ErbB3 is a member of the human epidermal
growth family (HER) of tyrosine kinase receptors that
also includes HER1/ErbB1, HER2/ErbB2 and HER4/
ErbB4. Of the four members, HER3 is classified as a
pseudokinase because it lacks two of the eleven residues
important for catalysis (Figure 1a, b and f). Upon ligand
binding to the EGF receptor, the intracellular kinase
domains undergo homodimerisation and heterodimeri-
sation resulting in the formation of active asymmetric
dimers (Figure 2c) [37,38]. The asymmetric dimersCurrent Opinion in Structural Biology 2010, 20:772–781
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and ‘the activator’ kinase (Figure 2c). The activator
binds via its C-lobe to the aC helix (N-lobe) of ‘the
receiver’, thus activating ‘the receiver’ kinase in a man-
ner that is reminiscent to the CDK2/cyclin mode of
activation (Figure 2c). Curiously, residues involved in
both ‘activator’ and ‘receiver’ interfaces (both N-lobe
and C-lobe) are conserved among all active kinases
HER1, 2 and 4 [39], suggesting that these can act as
both ‘activators’ and ‘receivers’. By contrast, only the C-
lobe residues that are involved in the role of the ‘acti-
vator’ are conserved in HER3 [39]. This suggests that
the HER3 pseudokinase is an allosteric activator of ‘the
receiver’ rather than catalyzing phosphoryltransfer
(Figure 2c). Consistent with this, a recently published
study of HER3 also revealed that the HER3 kinase
domain attains a conformation common to inactive
protein kinases [39]. In addition, constructs comprising
the tyrosine kinase domain and the intracellular kinase
domain (ICD) are incapable of phosphoryltransfer [39].
Intriguingly however, despite the relatively mild sub-
stitutions in the catalytic site (Figure 1f), a histidine-
tagged HER3–ICD construct was reported to possess
catalytic activity in the presence of vesicle lipids
attached to NTA-Ni head groups [22]. This measured
HER3 activity is 1000 fold less than the active HER1
counterpart [22,17] and it remains to be determined
whether this trace level of phosphorylation is biologi-
cally relevant.
VRK3
VRK3 is a human vaccinia related kinase and lacks
catalytic activity owing to the substitution of six out of
eleven active site residues (Figure 1a and b). The struc-
ture of VRK3 explains how non-conservative substi-
tutions of these catalytic motifs compromise VRK3
catalytic competence (Figure 1g) [40]. Of detrimental
effect to ATP binding and hence catalytic activity, are the
substitution of a small glycine residue from the glycine-
rich loop (residue Asp175) and residue Gln177 that are
predicted to clash with the phosphate moiety of ATP,
although similar substitutions are tolerated in ILK. In
addition, hydrophobic residues Leu180, Leu262 and
Phe313 now fill the ATP binding pocket and complete
the so-called ‘hydrophobic R-spine’ (Figure 1g) [41].
Consistent with these structural observations, VRK3 is
incapable of binding nucleotides [40]. The VRK3 struc-
ture is similar to the structure of the closely related active
kinase VRK2, although the inability to bind nucleotides
renders VRK3 a truly ‘dead’ kinase. Recent studies
suggest that VRK3 direct binding inhibits the vaccinia
H1-related (VHR) phosphatase, a dual-specificity phos-
phatase that dephosphorylates and inactivates ERK
[42,43]. Thus, VRK3 regulates MAP kinase signalling
through inhibition of ERK activity, and VRK3 functions
may be attributed to its interactions instead of function-
ing as a protein kinase.Current Opinion in Structural Biology 2010, 20:772–781ROP2 and ROP8
Two other pseudokinase structures, members of the
Rhotropy (ROP) family, ROP2 and ROP8 from the
intracellular parasite Toxoplasma gondii have been
reported recently [44,45]. Of the eight members of
the ROP family, five are predicted to be pseudokinases,
namely ROP2, ROP4, ROP5, ROP7 and ROP8. It is not
clear why so many members of the ROP family are
pseudokinases, although it is possible that they are
examples of evolutionary remnants of gene duplication,
given that the genome of these parasites is more amen-
able to undergo rapid changes. ROP2 and ROP8 lack
seven out of eleven conserved residues important for
catalysis and are predicted to be inactive (Figure 1a
and b). The structures of ROP2 and ROP8 adopt similar
conformations, with the activation segment in the cano-
nical conformation typical of active protein kinases
[44,45]. One noticeable difference is the presence of
a short insert within the aEF/aF loop, which may also
account for specific binding of as yet unidentified macro-
molecular partners. Unlike VRK3, the ATP pocket is
empty in ROP2 and ROP8 structures, and Labesse
et al. reported that ROP2 does not interact with ATP
[44]. Non-conservative substitutions from the N-lobe
residues Glu275 and Tyr278, (glycine-rich loop) as well as
residue Tyr280 (b2) are predicted to clash with a bound
ATP molecule (Figure 1h), although the adenine pocket
is not completely filled. Curiously, aMg2+ ion is present in
the ROP2/8 active site (Figure 1h), and this is coordinated
by an acquired Gly442Glu substitution in the conserved
Asp-Phe-Gly motif (Figure 1a). Hence, it is still uncertain
whether the nucleotide pocket of ROP pseudokinases
harbours a true ATP or other ligand binding site. The
catalytic base is also missing and is replaced by Tyr422
(Figure 1h), which further suggests ROP pseudokinases
are devoid of catalytic activity. Instead, their role is
predicted to be mainly of scaffolding nature.
Pseudokinases regulated by nucleotide
binding
The link between nucleotide pocket occupancy of a
kinase/pseudokinase domain and its conformation has
not been fully appreciated, despite potential functional
implications and examples in other classes of enzymes
that bind nucleotides (e.g. G-proteins are regulated by
guanine nucleotide-induced conformational changes).
Pseudokinases like STRADa and HER3 bind ATP with
low nanomolar affinity [28,22]. Structural, biophysical
and mutagenesis data demonstrate the importance of
nucleotide binding to STRADa in influencing STRA-
Da’s ability to interact with its biological partners (LKB1
and MO25), as well as the ability of STRADa to activate
the LKB1 tumour suppressor kinase [28,27].
Recently, conformational regulation of a kinase domain
through nucleotide pocket occupancy has also been
described for catalytically active kinases. For instancewww.sciencedirect.com
Pseudokinases-remnants of evolution or key allosteric regulators? Zeqiraj and van Aalten 777in the case of IRE1 (Inositol-requiring enzyme 1), its
phosphoryl transfer activity is functionally dispensable
[46]. Instead, the nucleotide binding event serves to
promote dimerisation that in turn composes a ribonu-
clease active site elsewhere on the protein. The kinase
domain dimerisation occurs mainly through the N-lobe,
including helix aC, and does not involve the activation
segment [46]. The authors suggest, that the predicted
pseudokinase RNaseL that is closely related to IRE1 but
lacks its activation segment and hence phosphotransfer
activity altogether, would similarly use nucleotide bind-
ing to promote RNaseL dimerisation and ribonuclease
function [46].
Another prominent example of a pseudokinase influ-
enced by ATP binding is the family of receptor guanylyl
cyclases (RGC), that produce the second messenger
cGMP in response to the binding of several natriuretic
factors (reviewed in [47]). These lack the HRDmotif that
provides the catalytic base residue, although ANP-RGC
receptors are able to bind ATP leading to further ampli-
fication of receptor activity. It is thought that both activity
of the guanyl cyclase domain, C-terminal to the pseudo-
kinase domain, as well as receptor ligand affinity are
influenced by ATP binding [48]. The ATP-dependent
activity of the receptor is not affected when non-hydro-
lysable forms of ATP (e.g. ATP-g-S) are used, and is
sensitive to point mutations in the glycine-rich loop and
VAIK motifs that affect ATP interaction with the pseu-
dokinase domain [49,47]. Moreover, Jaleel et al., 2006
raised a monoclonal antibody that recognises the pseu-
dokinase domain of guanylyl cyclase receptor 2C (GC-C)
and showed that the immunoreactivity was compromised
upon ATP binding, suggesting large conformational shifts
between the ATP bound/unbound forms of this domain
[50]. Fine epitopemapping revealed the epitope to be the
region around the VAIK motif. In the absence of struc-
tural data, it is difficult to envisage the exact confor-
mational changes that would occur owing to GC-C
ATP binding. In the majority of kinases the VAIK motif
(b3) is followed by helix aC, a well known region that
undergoes large conformational changes upon formation
of the conserved Lys(b3)/Glu(aC) ion bridge [6]. Future
studies in this area may demonstrate that the active/
inactive conformations of the pseudokinase domain are
indeed required for RGC activity via a regulatory mech-
anism that involves nucleotide binding.
Pseudokinases interacting with active kinases
EGF and Eph receptor tyrosine kinases
Interestingly, there are a number of membrane receptors
that contain a predicted cytoplasmic pseudokinase
domain, including members of the ephrin receptor
EphB6 and EphB10 as well as members of the epidermal
growth factor receptor family ErbB3/Her3. As already
discussed above the four members of the EGF receptor
kinases (ErbB1–4) are envisaged to trans-activate bywww.sciencedirect.comforming so-called asymmetric heterodimers, upon ligand
binding rather than phosphorylation [37,38]. This lack
of evolutionary pressure to conserve phosphoryl transfer
activity, owing to the presence of multiple ErbB genes
coupled by the allosteric mechanism of activation rather
than phosphorylation, may be the cause for the loss of
catalytic activity of ErbB3. It is possible that other pseu-
dokinases have also evolved in a similar way. Given the
proximity to the EGF receptor tyrosine kinases in the
human kinome, EphB6 and EphB10 may be regulating
the active members of the Eph receptor tyrosine kinase
family by using an as yet to be determined, analogous
trans-activation mechanism to ErbB3.
KSR
Another example where a pseudokinase forms complexes
with active kinases are members of the kinase suppressor
of Ras 1 and 2 (KSR1/2), that are essential for Ras induced
activation of the RAF-MEK-ERKmodule inMAP kinase
signalling. These predicted pseudokinases act as scaffolds
bringing together the three components of the MAP
kinase pathway (MAPKKK, MAPKK and MAPK), thus
regulating signalling output and potentiation [51–53].
The role of scaffold proteins in MAP kinase signalling
is well studied in budding yeast and the importance of
Ste5p adaptor protein for bringing together the MAPK
components module is well established [54–56]. It
appears the Ste5p scaffolding roles for MAP kinases in
yeast, have been substituted byKSR1 and KSR2 in higher
eukaryotes [57,51]. The pseudokinase domain of KSR1
binds MEK and RAF, whereas ERK is recruited to the
signalling complex via a conserved domain N-terminal to
the pseudokinase domain [51]. In addition, recent work
that established KSR2 as an important scaffold (similar to
KSR1) of MAP kinase signalling, reveals KSR2 can be
regulated by dephosphorylation by calcineurin in
response to changing Ca2+ levels [53]. The lack of struc-
tural information makes it difficult to precisely under-
stand the mechanism by which KSR1/2 contribute to
these scaffolding complexes, and what conformation
the KSR pseudokinase domain attains when acting as a
scaffold. It will be interesting however to investigate
ligand (ATP) binding capabilities of KSR1/2 and see if
this is required forMAP kinase signalling, and whether an
active conformation is required for KSR binding of macro-
molecular partners.
A prominent finding that suggests KSR may have func-
tions beyond the scaffolding component, came from the
recent revelation that RAF kinase domains form homo-
dimers and heterodimers resulting in activated RAF
kinase [58] (Figure 2d). This side-to-side dimerisation
interface engages a region in close proximity to the
regulatory helix aC and is required for RAF activation
(Figure 2d). The residues involved in the dimer interface
are also conserved in KSR, and Rajakulendran et al.
demonstrate that KSR can function as an allostericCurrent Opinion in Structural Biology 2010, 20:772–781
778 Proteinsactivator of RAF, without the requirement for KSR
phosphoryltransfer activity [58].
JAKs
Perhaps the most studied pseudokinase domain belongs
to the members of Janus tyrosine kinase (JAK) family.
The JAK isoforms include JAK1, JAK2, JAK3 and TYK2
all of which contain an N-terminal pseudokinase domain
(JH2) followed by a kinase domain (JH1). This charac-
teristic feature of containing two kinase domains gives
JAKs their name, referring to the two-faced Roman god
Janus. JAKs respond upon receptor binding to cytokines
and phosphorylate the cytoplasmic region of these cyto-
kine receptors, thus creating sites of interaction for
downstream signalling molecules. The pseudokinase
domain is required for JAK2 auto-inhibition and is
essential for JAK2 cytokine activation [59,60]. A gain-
of-function mutation (Val617Phe) in the JAK2 JH2
domain is a cause of myeloproliferative disorders in
humans [61–63]. Structural modelling and biochemical
data suggest the N-lobe of JH2 domain where Val617
resides is in close proximity to the JH1 domain [60].
Recently, gain-of-function somatic mutations of another
residue present in the JH2 domain (Arg683Gly/Ser/Lys)
were found in 18% of patients suffering with Down’s
syndrome-associated acute lymphoblastic leukaemia
[64–66]. The exact location of these disease causing
mutations and how their position relates to the JH1
domain are not known. It will be interesting to see if
structural studies of JH1/JH2 domains will reveal the
molecular mechanism of action of these mutations, and
whether these resemble any of the interactions that have
been recently described for other pseudokinase–kinase
interactions.
Evolution of pseudokinases
How did pseudokinases evolve? In general it is plausible
to believe that kinases evolved from ATP binding
enzymes, since nucleotide binding must have preceded
catalytic function. Therefore it is not surprising that
ligand (ATP) binding plays a key regulatory component
for pseudokinase/kinase function. As a consequence there
are two possibilities—either pseudokinases represent
‘would-be’ active kinases, or they represent kinases that
have lost their catalytic activity.
The first scenario could be true for proteins that are well
conserved as pseudokinases throughout eukaryotic
kinase evolution such as SCYL1-3 and GCN2. For
instance, ATP-binding precursors of yeast SCY1 and
GCN2 may have failed to ‘mature’ as active protein
kinases capable of phosphoryl transfer. Instead, import-
ant non-catalytic functions were conserved throughout
evolution for these pseudokinases. In GCN2 this could
have been aided by loss of evolutionary pressure for
kinase maturation, since another kinase domain is pre-
sent in the same polypeptide chain.Current Opinion in Structural Biology 2010, 20:772–781However, the reasoning above cannot account for a sig-
nificant number of pseudokinases that do not have clear
pseudokinase homologues in primitive species (e.g.
STRADa, KSR1/2, HER3, etc. . .). Therefore these
may have evolved via a different route. One possibility
is that pseudokinases have evolved from active kinases
once capable of phosphorylating and activating their
substrates, but have lost their activity during evolution.
The structures of STRADa, ILK and VRK3 show that
despite being inactive, these pseudokinases are able to
assume an active conformation with a highly organised
active site poised for phosphoryl transfer. In addition, the
structure of the LKB1 heterotrimer and ILK-a-parvin
complex, reveal that STRAD and ILK can bind LKB1
and a-parvin respectively as pseudosubstrates [27,36].
This suggests that pseudokinases like STRADa and ILK
were able to phosphorylate substrates at some stage
during evolution, but changed their mechanism to favour
regulation through binding, rather than post-translational
modification. It is possible that other pseudokinases have
evolved from active kinases in similar ways.
Going ‘pseudo’-loosing the will to catalyse
The process of using previously catalytically competent
domains as scaffolds is plausible from an evolutionary
perspective as enzymes have evolved to bind their sub-
strates. This is also observed in other classes of enzymes
such as pseudophosphatases [67], and similar to some
pseudokinases, these enzymes lack catalytically import-
ant residues and act as scaffolds in signalling complexes.
For instance the pseudophosphatase TAB1 is a scaffold-
ing component of the TAK1-TAK2/3-TAB1 signalling
complex [68]. In addition, a number of PTPs (protein
tyrosine phosphatases) are predicted to be inactive
[67,69]. Examples of predicted pseudophosphatases in-
clude STYX [67], EGG-4 and EGG-5 [70] that are
thought to function by binding and ‘trapping’ phosphory-
lated tyrosine residues instead of phosphate removal. The
exact mechanisms of action for these pseudophosphatases
are as yet unclear, although engaging phosphotyrosine
residues through this ‘substrate trapping’ mechanism will
neutralise the effects of phosphorylation, and/or make
them inaccessible for signal-transmitting phosphotyro-
sine binding domains (e.g. SH2 domains) [70].
The phenomenon of catalytically inactive members is not
restricted to enzyme families involved in protein phos-
phorylation alone, but extends to other processes of
postranslational modifications such as ubiquitinylation.
A class of ubiquitin E2 ligases called Uev (ubiquitin
E2 variant) domains have the same fold as E2 enzymes
but lack certain catalytic residues and are hence devoid of
catalytic activity [71]. Similar to the process by which
some kinases require pseudokinases for full activity, some
E2 enzymes also require their inactive counterparts (Uev
domains) for ability to transfer ubiquitin to a substrate
(e.g. Uev1a and Ubc13). By analogy to the existence ofwww.sciencedirect.com
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ber (12%) of ubiquitin specific proteases (DUSPs) lack
conserved catalytic residues and are predicted to be
inactive [72]. It is possible that the number of predicted
inactive DUSPs may be an overestimate, and after further
examination some of these DUSPs may indeed turn out
to be active. However, important non-catalytic functions
that utilise DUSPs’ ability to recognise ubiquitin and
function through a similar ‘substrate trapping’ mechanism
described for pseudophosphatases [70], are possible. The
prevalence of non-catalytic functions may relieve the
evolutionary pressure for conservation of key catalytic
residues and may explain why some of these enzymes
appear to be inactive. It also provides an example of
nature’s ability to repurpose already perfected molecular
units in many different ways.
Concluding remarks
In recent years, a burst of studies have provided valuable
insights into the biological functions and the mechanism
of action of pseudokinases. An important revelation is that
the initially predicted fraction of kinases that are truly
‘dead’, 10% of the human kinome, may have been an
overestimate. Despite variations in the catalytic motifs of
pseudokinases, nature has acquired alternative mechan-
isms to correct for the missing functions in phosphoryl
transfer, by making use of the versatile kinase fold.
Exhaustive structural studies of protein kinases have
established that the kinase/pseudokinase domain is
plastic, and attains many different conformations in
response to binding of micromolecular and macromolecu-
lar ligands. Similarly, large conformational changes occur
upon postranslational modifications such as phosphoryl-
ation. Therefore, pseudokinases can be envisaged as
‘elastic’ scaffolds, bringing together components of a
particular signalling network, as well as being allosteric
activators of protein kinases.
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